Treprostinil (L606) vs Treprostinil (Tyvaso)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Pulmonary Arterial Hypertension
Shared mechanism: IP receptor (prostacyclin pathway) · full Pulmonary Arterial Hypertension pipeline
Treprostinil (L606)
Developed by Liquidia Corporation under a licence from Pharmosa Biopharm Inc.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Treprostinil (Tyvaso)
Marketed by United Therapeutics
NCT00147199 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial of 235 participants, with 115 receiving inhaled treprostinil and 120 receiving placebo. The prespecified clinical primary endpoint—change in peak 6-minute walk distance at Week 12—was met, with a between-group estimate of 20.0 meters (95% CI 8.0–32.8; p=0.00044).
Next expected readout: December 2027 · NCT07177703 (registry estimate)
Reported efficacy
Peak 6-minute Walk Distance (12 weeks): Peak 6-minute Walk Distance (12 weeks): Inhaled Treprostinil — Week 12: 366 meters (IQR 300 to 423); Change from Baseline: 21.6 meters (IQR -8 to 54) vs Placebo — Week 12: 360 meters (IQR 296 to 414.9); Change from Baseline: 3 meters (IQR -26 to 31.5) (met)
Result source: NCT00147199
Results for Pulmonary Arterial Hypertension
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Treprostinil (L606): no structured comparison results are available for Pulmonary Arterial Hypertension.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Treprostinil (Tyvaso)
show 1 more result
show 1 more result
+ 3 further endpoints in the CSV export.
Available safety results
Treprostinil (Tyvaso)
| Dropout rate | 11.3% NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3 show 3 more results0% NCT01268553 · Phase 4 · registry result, not featured evidence 11% NCT00741819 · Phase 4 · registry result, not featured evidence 0% NCT00705133 · Phase 2 · registry result, not featured evidence |
|---|---|
| Discontinued due to AEs | — NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3 show 3 more results— NCT01268553 · Phase 4 · registry result, not featured evidence 4.1% NCT00741819 · Phase 4 · registry result, not featured evidence — NCT00705133 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 7.8% NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3 show 3 more results0% NCT01268553 · Phase 4 · registry result, not featured evidence 13.7% NCT00741819 · Phase 4 · registry result, not featured evidence 0% NCT00705133 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | cough 53.9% (placebo 29.2%) headache 40.9% (placebo 22.5%) nausea 19.1% (placebo 10.8%) NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3 show 2 more resultsgeneral prostacyclin adverse reaction profile 100% NCT00705133 · Phase 2 · registry result, not featured evidence |
Pulmonary Hypertension Associated with Interstitial Lung Disease
Shared mechanism: IP receptor (prostacyclin pathway) · full Pulmonary Hypertension Associated with Interstitial Lung Disease pipeline
Treprostinil (L606)
Developed by Liquidia Corporation under a licence from Pharmosa Biopharm Inc.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: July 2029 · NCT07285655 (registry estimate)
No aligned efficacy figure on record for this race.
Treprostinil (Tyvaso)
Marketed by United Therapeutics
NCT02630316 · Phase 2/3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial of 326 people, and inhaled treprostinil significantly improved six-minute walk distance at week 16 compared with placebo (p=0.0043). The trial reported a sample-size calculation for this endpoint and enrolled more participants than the calculation required.
Reported efficacy
Change in 6-minute Walk Distance (6MWD) Measured at Peak Exposure From Baseline to Week 16 (Baseline and Week 16): Change in peak 6-minute walk distance from baseline to week 16: inhaled treprostinil median +6.0 m vs placebo -9.0 m (n=163 each); Hodges-Lehmann difference 21.0 m (95% CI 7.0 to 37.0), p=0.0043 (CT.gov posted results). (met)
Result source: NCT02630316
Results for Pulmonary Hypertension Associated with Interstitial Lung Disease
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Treprostinil (L606): no structured comparison results are available for Pulmonary Hypertension Associated with Interstitial Lung Disease.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Treprostinil (Tyvaso)
show 1 more result
Available safety results
Treprostinil (Tyvaso)
| Dropout rate | —Active Inhaled Treprostinil NCT02630316 · Phase 2/3 show 1 more result20.2%Inhaled Treprostinil NCT02630316 · Phase 2/3 |
|---|---|
| Discontinued due to AEs | —Active Inhaled Treprostinil NCT02630316 · Phase 2/3 show 1 more result—Inhaled Treprostinil NCT02630316 · Phase 2/3 |
| Serious AEs | 23.3%Active Inhaled Treprostinil NCT02630316 · Phase 2/3 show 1 more result—Inhaled Treprostinil NCT02630316 · Phase 2/3 |
| Most frequent reported AEs | cough 43.6% (placebo 33.1%) headache 27.6% (placebo 19.6%) dyspnoea 25.2% (placebo 31.3%) NCT02630316 · Phase 2/3 |
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Treprostinil (L606)'s landscape · Treprostinil (Tyvaso)'s landscape